Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.

Therapeutic strategies to target RAS-mutant cancers

Ryan, Meagan B., Corcoran, Ryan B. · 2018 · Nature Reviews Clinical Oncology

Abstract

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, leading researchers to test numerous alternative strategies aimed at exploiting RAS-related vulnerabilities or targeting RAS effectors. In the past few years, we have witnessed renewed efforts to target RAS directly, with several promising strategies being tested in clinical trials at different stages of completion. Important advances have also been made in approaches designed to indirectly target RAS by improving inhibition of RAS effectors, exploiting synthetic lethal interactions or metabolic dependencies, using therapeutic combination strategies or harnessing the immune system. In this Review, we describe historical and ongoing efforts to target RAS-mutant cancers and outline the current therapeutic landscape in the collective quest to overcome the effects of this crucial oncogene.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-018-0105-0

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 178 references

Cited by

See all 435

Metadata

Authors
Ryan, M. B., & Corcoran, R. B.
Affiliations
Harvard University (US)
Corresponding author
Corcoran, Ryan B.
Venue
Nature Reviews Clinical Oncology
Published
2018-10-01
Volume
15
Issue
11
Pages
709-720
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W2893018770
Cited by
420
References
178
Citations by year
2026: 48 · 2025: 40 · 2024: 50 · 2023: 49 · 2022: 115 · 2021: 67 · 2020: 34 · 2019: 16 · 2018: 1
FWCI
2.91
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • AstraZeneca
  • Sanofi
  • National Institutes of Health
  • Stand Up To Cancer
  • National Cancer Institute (P50CA127003, R01CA208437, U54CA224068)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
RAS mutations, RAS-mutant cancers, RAS inhibitors, Ras effectors, synthetic lethality, metabolic dependencies, combination therapy, cancer immunotherapy, oncogene addiction, clinical trials
MeSH terms
Antineoplastic Agents, Humans, Mutation, Neoplasms, Signal Transduction, ras Proteins, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic strategies to target RAS-mutant cancers. https://app.cochat.ai/papers/10.1038/s41571-018-0105-0
The paper
Ryan, M. B., & Corcoran, R. B. (2018). Therapeutic strategies to target RAS-mutant cancers. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-018-0105-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.